P

Porton Pharma Solutions Ltd
SZSE:300363

Watchlist Manager
Porton Pharma Solutions Ltd
SZSE:300363
Watchlist
Price: 17.2 CNY -5.29% Market Closed
Market Cap: 9.4B CNY
Have any thoughts about
Porton Pharma Solutions Ltd?
Write Note

Porton Pharma Solutions Ltd
Common Shares Outstanding

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Porton Pharma Solutions Ltd
Common Shares Outstanding Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Shares Outstanding CAGR 3Y CAGR 5Y CAGR 10Y
P
Porton Pharma Solutions Ltd
SZSE:300363
Common Shares Outstanding
ÂĄ546m
CAGR 3-Years
1%
CAGR 5-Years
0%
CAGR 10-Years
3%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Common Shares Outstanding
ÂĄ5.9B
CAGR 3-Years
0%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Common Shares Outstanding
ÂĄ603.3m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
0%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Common Shares Outstanding
ÂĄ6.4B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
0%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Common Shares Outstanding
ÂĄ1.8B
CAGR 3-Years
0%
CAGR 5-Years
11%
CAGR 10-Years
6%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Common Shares Outstanding
ÂĄ401m
CAGR 3-Years
0%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Porton Pharma Solutions Ltd
Glance View

Market Cap
9.4B CNY
Industry
Pharmaceuticals

Porton Pharma Solutions Ltd. engages in the research and development and manufacture of pharmaceutical products and active pharmaceutical ingredients. The company is headquartered in Chongqing, Chongqing and currently employs 3,782 full-time employees. The company went IPO on 2014-01-29. The firm is also engaged in the multi-client product manufacturing businesses and pharmaceutical and chemical commerce businesses. The products of the Company include anti-viral, anti-diabetic, hypolipidemic, anti-cancer, anesthesia analgesia and anti-bacterial pharmaceuticals, among others. The firm operates its businesses in Europe, North America, Asia and China, among others.

Intrinsic Value
20.26 CNY
Undervaluation 15%
Intrinsic Value
Price
P

See Also

What is Porton Pharma Solutions Ltd's Common Shares Outstanding?
Common Shares Outstanding
546m CNY

Based on the financial report for Sep 30, 2024, Porton Pharma Solutions Ltd's Common Shares Outstanding amounts to 546m CNY.

What is Porton Pharma Solutions Ltd's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 10Y
3%

Over the last year, the Common Shares Outstanding growth was 1%. The average annual Common Shares Outstanding growth rates for Porton Pharma Solutions Ltd have been 1% over the past three years , and 3% over the past ten years .

Back to Top